Barchart.com
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Innovative Industrial Properties (IIPR)

Innovative Industrial Properties (IIPR)
50.00 x 400 52.50 x 100
Post-market by (Cboe BZX)
50.96 +0.48 (+0.95%) 04/16/25 [NYSE]
50.00 x 400 52.50 x 100
Post-market 50.96 unch (unch) 16:01 ET
Quote Overview for Wed, Apr 16th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Day Low
50.00
Day High
51.86
Open 50.23
Previous Close 50.48 50.48
Volume 216,500 216,500
Avg Vol 531,810 531,810
Stochastic %K 25.97% 25.97%
Weighted Alpha -50.83 -50.83
5-Day Change -0.84 (-1.62%) -0.84 (-1.62%)
52-Week Range 45.44 - 138.35 45.44 - 138.35
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
 Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,430,199
  • Shares Outstanding, K 28,332
  • Annual Sales, $ 308,520 K
  • Annual Income, $ 161,660 K
  • EBIT $ 239 M
  • EBITDA $ 311 M
  • 60-Month Beta 1.59
  • Price/Sales 4.67
  • Price/Cash Flow 6.16
  • Price/Book 0.75

Options Overview Details

View History
  • Implied Volatility 61.31% ( +3.76%)
  • Historical Volatility 71.24%
  • IV Percentile 98%
  • IV Rank 80.97%
  • IV High 70.26% on 04/08/25
  • IV Low 23.22% on 08/21/24
  • Put/Call Vol Ratio 5.84
  • Today's Volume 520
  • Volume Avg (30-Day) 652
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 13,061
  • Open Int (30-Day) 11,170

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.84
  • Number of Estimates 3
  • High Estimate 1.91
  • Low Estimate 1.76
  • Prior Year 2.21
  • Growth Rate Est. (year over year) -16.74%
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.
Get delivered to your inbox for FREE:
Sign Up.

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.44 +12.15%
on 04/09/25
Period Open: 69.62
66.46 -23.32%
on 03/17/25
-18.66 (-26.80%)
since 03/14/25
3-Month
45.44 +12.15%
on 04/09/25
Period Open: 66.94
75.71 -32.69%
on 02/14/25
-15.98 (-23.87%)
since 01/16/25
52-Week
45.44 +12.15%
on 04/09/25
Period Open: 94.49
138.35 -63.17%
on 09/24/24
-43.53 (-46.07%)
since 04/16/24

Most Recent Stories

More News
Why Shares of Innovative Industrial Properties Sank This Week Motley Fool - Fri Apr 4, 9:43AM CDT

The one event that strikes true fear into the heart of real estate investment trust (REIT) investors is the tenant default.

IIPR : 50.96 (+0.95%)
Fearless Girl statue New York by Vivalapenler via iStock
Equity Markets Recover on Strength in Defensive Stocks and Energy Producers Barchart - Mon Mar 31, 3:46PM CDT

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.55%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.00%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.02%. June E-mini S&P...

ALK : 44.65 (-2.57%)
IIPR : 50.96 (+0.95%)
MPC : 124.07 (+1.51%)
GOOGL : 153.33 (-1.91%)
AAPL : 194.27 (-3.89%)
HRL : 30.18 (-0.66%)
SRPT : 53.94 (-0.88%)
OXY : 38.45 (+1.72%)
TSLA : 241.55 (-4.94%)
FANG : 130.22 (+2.42%)
SPY : 525.66 (-2.22%)
AIG : 80.97 (-1.20%)
Wall Street sign in lower Manhattan New York by Stuart Monk via Shutterstock
Stocks Mixed on Tariff Concerns Barchart - Mon Mar 31, 10:31AM CDT

The S&P 500 Index ($SPX ) (SPY ) today is up +0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.78%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.49%. After a lower open, stock indexes...

ALK : 44.65 (-2.57%)
IIPR : 50.96 (+0.95%)
GOOGL : 153.33 (-1.91%)
TAP : 58.71 (-1.34%)
HRL : 30.18 (-0.66%)
SRPT : 53.94 (-0.88%)
KHC : 28.81 (-2.07%)
TSLA : 241.55 (-4.94%)
KDP : 35.11 (-0.79%)
AMD : 88.29 (-7.35%)
SPY : 525.66 (-2.22%)
AIG : 80.97 (-1.20%)
Road sign of New York Wall street corner Broad street by Mezzotint via Shutterstock
Global Equity Markets Slide on US Tariff Concerns Barchart - Mon Mar 31, 9:12AM CDT

The S&P 500 Index ($SPX ) (SPY ) today is down -1.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.00%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.30%. June E-mini S&P futures...

MSTR : 311.66 (+0.30%)
IIPR : 50.96 (+0.95%)
GOOGL : 153.33 (-1.91%)
AAPL : 194.27 (-3.89%)
HRL : 30.18 (-0.66%)
SRPT : 53.94 (-0.88%)
KHC : 28.81 (-2.07%)
COIN : 172.21 (-1.91%)
TSLA : 241.55 (-4.94%)
AMD : 88.29 (-7.35%)
SPY : 525.66 (-2.22%)
META : 502.31 (-3.68%)
Real estate, development and investing concept by Who is Danny via Shutterstock
This REIT ETF Just Hit a 52-Week Low. Here’s Why It’s Time to Buy. Barchart - Wed Mar 26, 8:17AM CDT

Twenty-two ETFs hit 52-week highs, and 17 hit 52-week lows on Tuesday. One of the ETFs hitting a 52-week low was an Invesco REIT that’s worth considering for income-focused investors. Here’s why.

YOLO : 1.6944 (+2.07%)
IIPR : 50.96 (+0.95%)
KBWY : 15.27 (+0.07%)
Better Beaten-Down Dividend Stock to Buy: Innovative Industrial Properties or Medical Properties Trust? Motley Fool - Thu Mar 20, 6:40AM CDT

Real estate investment trusts (REIT) are a favorite target of income-seeking investors, since the law requires them to distribute most of their earnings as dividends to maintain their tax-advantaged status....

IIPR : 50.96 (+0.95%)
MPW : 5.39 (-0.92%)
Beat the Nasdaq With This Cash-Gushing Dividend Stock Motley Fool - Tue Mar 18, 3:20AM CDT

If you're looking for market-beating stocks, it can sometimes be good to travel a bit off the beaten path to find more unusual options. Innovative Industrial Properties (NYSE: IIPR) offers just such an...

IIPR : 50.96 (+0.95%)
Is the Options Market Predicting a Spike in Innovative Industrial Properties (IIPR) Stock?
Is the Options Market Predicting a Spike in Innovative Industrial Properties (IIPR) Stock? Zacks Investment Research - Wed Mar 12, 3:20PM CDT

Investors in Innovative Industrial Properties, Inc. IIPR need to pay close attention to the stock based on moves in the options market lately. That is because the April 17, 2025 $115 Put had some of the...

IIPR : 50.96 (+0.95%)
Better Dividend Stock: Innovative Industrial Properties vs. AGNC Investment Motley Fool - Sun Mar 2, 3:39AM CST

The big reason investors should be looking at Innovative Industrial Properties (NYSE: IIPR) and AGNC Investment (NASDAQ: AGNC) today are their dividend yields. Innovative Industrial's yield is a huge 10%,...

IIPR : 50.96 (+0.95%)
AGNC : 8.30 (-1.31%)
Prediction: Innovative Industrial Properties Will Beat the Market. Here's Why Motley Fool - Thu Feb 27, 6:00PM CST

In this insightful video, Tyler Crowe, and Jason Hall evaluate Innovative Industrial Properties (NYSE: IIPR), a REIT focused on medical-use cannabis facilities. They provide ratings on various aspects...

IIPR : 50.96 (+0.95%)
NVDA : 104.49 (-6.87%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire - Mon Sep 4, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Erik Penser Bank Company Event PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir's patent application for fostrox approved in China PR Newswire - Mon Jun 19, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima PR Newswire - Fri Jun 2, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Redeye Growth Day PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Change in the number of shares and votes in Medivir AB (publ) PR Newswire - Wed May 31, 2023

/PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May...

IGMS : 1.1900 (-6.30%)
Medivir to present at the ABGSC Life Science Summit PR Newswire - Tue May 30, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire - Mon Sep 4, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Erik Penser Bank Company Event PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir's patent application for fostrox approved in China PR Newswire - Mon Jun 19, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima PR Newswire - Fri Jun 2, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Redeye Growth Day PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Change in the number of shares and votes in Medivir AB (publ) PR Newswire - Wed May 31, 2023

/PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May...

IGMS : 1.1900 (-6.30%)
Medivir to present at the ABGSC Life Science Summit PR Newswire - Tue May 30, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire - Mon Sep 4, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Erik Penser Bank Company Event PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir's patent application for fostrox approved in China PR Newswire - Mon Jun 19, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima PR Newswire - Fri Jun 2, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Redeye Growth Day PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Change in the number of shares and votes in Medivir AB (publ) PR Newswire - Wed May 31, 2023

/PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May...

IGMS : 1.1900 (-6.30%)
Medivir to present at the ABGSC Life Science Summit PR Newswire - Tue May 30, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
More news for this symbol

Barchart Technical Opinion

Strong sell

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Innovative Industrial Properties, Inc. is a real estate investment trust. It focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for medical-use cannabis facilities. Innovative Industrial Properties, Inc. is based in...

See More

IIPR Related ETFs

Managed Assets
Percent
Symbol %Holdings 3M %Chg
IIPR -23.87%
Innovative Industrial Properties
ESGV 1% -12.82%
ESG U.S. Stock Vanguard ETF
IJR 0.12% -18.82%
S&P Smallcap Ishares Core ETF
VNQ 0.11% -4.63%
Real Estate Vanguard ETF
IWM 0.06% -17.60%
Russell 2000 Ishares ETF
VB 0.03% -17.08%
Smallcap ETF Vanguard
Symbol %Holdings 3M %Chg
IIPR -23.87%
Innovative Industrial Properties
CNBS 2.84% -28.91%
Amplify Seymour Cannabis ETF
KBWY 2.16% -14.07%
KBW Premium Yield Equity REIT Invesco ETF
ESGV 1% -12.82%
ESG U.S. Stock Vanguard ETF
BLDG 0.89% -8.24%
Cambria Global Real Estate ETF
FYT 0.65% -20.37%
Smallcap Value Alphadex Fund FT

IIPR Related stocks

Symbol Last 3M %Chg
IIPR 50.96 -23.87%
Innovative Industrial Properties
AMT 218.00 +14.69%
American Tower Corp
WELL 145.63 +13.13%
Welltower Inc
PLD 100.29 -9.59%
Prologis Inc
PSA 289.03 -2.91%
Public Storage
DLR 148.18 -17.72%
Digital Realty Trust

Compare Symbols

Key Turning Points

Daily
52-Week
3rd Resistance Point 53.74
2nd Resistance Point 52.80
1st Resistance Point 51.88
Last Price 50.96
1st Support Level 50.02
2nd Support Level 49.08
3rd Support Level 48.16

See More

52-Week High 138.35
Fibonacci 61.8% 102.86
Fibonacci 50% 91.90
Fibonacci 38.2% 80.93
Last Price 50.96
52-Week Low 45.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro
Wed, Apr 23, 2025 5:00 PM UTC
Reserve Your Spot

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.

Start 30-Day Risk Free Trial